Upon realizing the potential of digital biomanufacturing over traditional processes, players are actively undertaking initiatives to adopt advanced platforms to drive operational excellence, visibility, control and synchronization in bioprocessing Roots Analysis is pleased to announce the publication of its recent study, titled, “Digital Biomanufacturing Market, 2023-2035.” The report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different regions. Amongst other elements, the report includes:  An executive summary of the insights captured during our research, offering a high-level view on the current state of the digital manufacturing market and its likely evolution in the mid-long term.  A general introduction to digital biomanufacturing, featuring a detailed discussion on various types of technologies that support digital bioprocessing. In addition, it presents the key challenges and future perspectives associated with the employment of digital technologies in the field of biomanufacturing.  A detailed assessment of the overall market landscape of companies offering digital manufacturing technologies (PAT, DAS, MES and digital twins), based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of company (CDMO provider and software provider), number of platforms offered, deployment options (cloud based, on-premises, corporate datacenter and hybrid), platform capabilities (process automation, bioprocess optimization and controls, process connectivity, scalability, data integration, process monitoring and visualization, performance analysis, report generation and documentation, smart manufacturing, document control, production tracking, performance analysis and data integration), software capabilities (process intelligence, data integration, real-time process monitoring, data visualization, performance analysis and control prediction, reporting and data management), type(s) of biologic(s) manufactured, other compatible platforms (artificial intelligence / machine learning / cloud based, big data, internet of things, augmented reality and virtual reality) and type of end user(s) (industry and non-industry), integrating software (enterprise resource planning (ERP), manufacturing operation management (MOM), product lifecycle management (PLM), human resource management (HRM)), type of service(s) offered (training, implementation / upgradation and general support), area(s) of application (asset / process management, clinical trials, personalized treatment, medical training, surgical planning, health monitoring and diagnosis).  A detailed competitiveness analysis of digital biomanufacturing technologies (PAT, DAS, MES and digital twins), based on supplier strength (in terms of years of experience and company size), technology portfolio (considering deployment options, number of platform capabilities, type of end user(s), software capabilities, area(s) of application, type(s) of twin(s)) and type(s) of biologic(s) manufactured.  Elaborate profiles of key players (companies offering more than one platform and established before 2012) engaged in the digital biomanufacturing domain, which are actively providing software based on PAT, DAS, MES and digital twins. Each profile includes a brief overview of the company, along with information on capabilities of digital technologies offered by these firms, recent developments and an informed future outlook.  A benchmark analysis highlighting the capabilities of companies (in terms of their expertise across various platforms related to the manufacturing of biologics) engaged in this domain, across key peer groups.  An analysis featuring information on recent partnerships inked between stakeholders engaged in this domain, based on several relevant parameters, such as year of partnership, type of partnership, type of technology, most active players (in terms of number of deals inked) and regional distribution of partnership activity, during the period 2018-2022.  A detailed analysis highlighting the market concentration of key industry stakeholders (companies offering more than one platform) across various regions, based on prevalent parameters, such as years of entrance, company size, type of technology, number of platforms offered and number of partnerships inked.  A detailed industry lifecycle analysis that indicates various stages, including emergence, growth, maturation and eventual decline for the digital biomanufacturing industry. The primary purpose of this analysis is to develop a better understanding of the current position / phase of the industry on the lifecycle chart (based on historical trends, partnership activity and various investments made by players engaged in this domain) and predict the upcoming events that are likely to drive the growth of this domain. Further, it presents short-term and long-term impacts of various key parameters that are expected to highly impact the wider adoption of digitalization in the field of biomanufacturing.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Type of Technology  Process Analytical Technology (PAT)  Data Analysis Software (DAS)  Manufacturing Execution Systems (MES)  Digital Twins  Deployment Options  Cloud-based Deployment Options  On-premises Deployment Options  Type(s) of Biologic(s) Manufactured  Antibodies  Cell and Gene Therapies  Proteins  Vaccines  Others  Geographical Regions  North America  Europe  Asia Pacific  Latin America  Middle East and North America Key companies / organizations covered in the report  AspenTech  Bioreactors.net  Dassault Systèmes  FUJIFILM Diosynth Biotechnologies  GE Healthcare  Körber  Merck  Sartorius  Thermo Fisher Scientific To view more details on this report, click on the link https://www.rootsanalysis.com/reports/digital-biomanufacturing-market.html Learn from experts: do you know about these emerging industry trends? TCR Therapies: An Emerging Therapeutic Modality Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Learn more about Roots Analysis consulting services: Roots Analysis Consulting - the preferred research partner for global firms Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com